Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes - Concepedia

Concepedia

Publication | Open Access

Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes

DOI Full Paper Access

47

Citations

19

References

2017

Year

Heike Zimdahl, Axel Haupt, Michael Brendel, Louis Bour, Fausto Machicao, Afshin Salsali, Uli C. Broedl, Hans‐Juergen Woerle, Hans‐Ulrich Häring, Harald Staiger

Pharmacogenetics and Genomics

Abstract

Common genetic variants in the SLC5A2 gene neither affects diabetes-related metabolic traits nor have a clinically relevant impact on response to treatment with the SGLT2 inhibitor empagliflozin.

References

	Year	Citations
DNA sequencing with chain-terminating inhibitors Frederick Sanger, S. Nicklen, Alan Coulson Proceedings of the National Academy of Sciences DnaEngineeringDna AnalysisMolecular BiologyMolecular Genetics	1977	69.1K
Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man David R. Matthews, J P Hosker, A. Rudenski, Diabetologia Insulin ResistanceObesityMetabolic SyndromeBody CompositionHealth Sciences	1985	31K
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation Andrew S. Levey, Juan Bosch, Julia B. Lewis, Annals of Internal Medicine	1999	15K
Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Masafumi Matsuda, Ralph A. DeFronzo Diabetes Care	1999	5.5K
Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial Michael Roden, Jianping Weng, Jens Eilbracht, The Lancet Diabetes & Endocrinology Diabetes ManagementCardiovascular DiseaseMedicineDiabetesActive Comparator	2013	438
Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Diabetes Care	2014	383
Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial Christopher S. Kovács, V Seshiah, Ros Swallow, Diabetes Obesity and Metabolism	2013	379
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes Hans‐Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Diabetes Care	2013	368
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria René Santer, Martina Kinner, C.L. Lassen, Journal of the American Society of Nephrology	2003	298
Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia Timo Rieg, Takahiro Masuda, Maria Gerasimova, American Journal of Physiology-Renal Physiology	2013	296

Page 1